Janux Therapeutics (JANX) Non Operating Income (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Non Operating Income data on file, last reported at $9.9 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 13.5% year-over-year to $9.9 million in Q1 2026; TTM through Mar 2026 was $42.5 million, a 18.59% increase from a year earlier, with the FY2025 full-year figure at $44.0 million, up 47.53% from the prior year.
• Non Operating Income for Q1 2026 stood at $9.9 million, down from $10.5 million in the prior quarter.
• Over the last five years, Non Operating Income for JANX reached as high as $11.4 million in Q1 2025 and fell as low as $132000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $6.0 million across 5 years, with a median of $5.4 million in 2024.
• Across the five-year window, Non Operating Income soared 2874.32% in 2022 and fell 13.5% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $2.2 million in 2022, then surged by 98.96% to $4.4 million in 2023, then surged by 101.1% to $8.8 million in 2024, then rose by 18.73% to $10.5 million in 2025, then retreated by 5.77% to $9.9 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $9.9 million in Q1 2026, $10.5 million in Q4 2025, and $10.9 million in Q3 2025.